|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | ||
| Stock-based compensation expense | ||
| Loss on fixed asset disposal | ||
| Provision for credit losses | ||
| Accretion of discount on marketable securities, net | ||
| Litigation settlement | ||
| Nonrelated Party | ||
| Related Party | ||
| Total litigation settlement | ||
| Loss on debt extinguishment | ||
| Change in fair value of contingent consideration | ||
| Changes in operating assets and liabilities: | ||
| Accounts receivable | ||
| Contract assets | ||
| Prepaid expense and other current assets | ||
| Other assets | ||
| Accounts payable | ||
| Accrued expenses and other current liabilities | ||
| Accrued income taxes | ||
| Deferred revenue | ||
| Other non-current liabilities | ||
| Net cash used in operating activities | ||
| Cash flows from investing activities: | ||
| Purchases of marketable securities | ||
| Sales of marketable securities | ||
| Maturities of marketable securities | ||
| Proceeds from fixed asset disposal | ||
| Purchases of property and equipment | ||
| Acquisition of businesses | ||
| Net cash provided by (used in) investing activities | ||
| Cash flows from financing activities: | ||
| Proceeds from initial public offering, net of underwriting fees | ||
| Proceeds from issuance of convertible note, net of debt issuance costs | ||
| Proceeds from loan facility | ||
| Repayment of loan facility | ||
| Proceeds from related party line of credit | ||
| Repayment of related party line of credit | ||
| Proceeds from issuance of common stock for share-based awards | ||
| Payroll taxes related to shares withheld from employees | ||
| Deferred transaction costs | ||
| Contingent consideration | ||
| Payments of vendor financing obligation | ||
| Net cash (used in) provided by financing activities | ||
| Effect of exchange rate fluctuations on cash, cash equivalents and restricted cash | ||
| Net (decrease) increase in cash and cash equivalents | ||
| Cash, cash equivalents and restricted cash, beginning of period | ||
| Cash, cash equivalents and restricted cash, end of period | ||
| Supplemental disclosures of cash flow information: | ||
| Income taxes paid | ||
| Interest paid | ||
| Noncash investing and financing activities: | ||
| Deferred offering costs incurred, not yet paid | ||
| Right-of use assets obtained in exchange for operating lease liabilities | ||
| Fair value of common stock issued in acquisition of businesses | ||
| Issuance of equity upon Micron Note conversion | ||
| Financial obligation incurred upon purchase of NXP IP | ||
| Cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | ||
| Restricted cash |
Loading...
